Mucosis BV
🇳🇱Netherlands
- Country
- 🇳🇱Netherlands
- Ownership
- Private
- Established
- 2006-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.mucosis.com
Phase I Study for SynGEM, an Intranasal Respiratory Syncytial Virus (RSV) Prefusion F Subunit Candidate Vaccine
Phase 1
- Conditions
- Respiratory Syncytial Viral Infections
- Interventions
- Biological: SynGEMOther: placebo
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2017-09-08
- Lead Sponsor
- Mucosis BV
- Target Recruit Count
- 48
- Registration Number
- NCT02958540
- Locations
- 🇬🇧
Imperial Centre for Translational and Experimental Medicine Hammersmith Hospital, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath